# Contents

Preface xiv  
Acknowledgments xv  
About the companion website xvi

## Introduction

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Components of a standard cytogenetics report, normal results and culture failures</td>
</tr>
<tr>
<td>2</td>
<td>Mosaicism</td>
</tr>
<tr>
<td>3</td>
<td>Autosomal trisomies — prenatal and livebirths</td>
</tr>
<tr>
<td>4</td>
<td>Translocations</td>
</tr>
</tbody>
</table>

### 1 Components of a standard cytogenetics report, normal results and culture failures

- 1.1 Components of a standard cytogenetics report 9
- 1.2 Prenatal normal results 17
- 1.3 Neonatal normal results 22
- 1.4 Normal variants in the population 23
- 1.5 Disclaimers and recommendations 29
- 1.6 Culture failures 30
- 1.7 Contamination 32

### 2 Mosaicism

- 2.1 Normal results with 30–50 cells examined 37
- 2.2 Normal and abnormal cell lines 37
- 2.3 Two or more abnormal cell lines 39

### 3 Autosomal trisomies — prenatal and livebirths

- 3.1 Introduction 41
- 3.2 Trisomy 21 — Down syndrome 42
- 3.3 Mosaic trisomy 21 — mosaic Down syndrome 43
- 3.4 Trisomy 13 — Patau syndrome 44
- 3.5 Trisomy 18 — Edwards syndrome 45
- 3.6 Trisomy 8 — mosaic 46
- 3.7 Trisomy 9 — mosaic 47
- 3.8 Trisomy 20 — mosaic, prenatal 47
- 3.9 Trisomy 22 — mosaic, prenatal 48

### 4 Translocations

- 4.1 Reciprocal (balanced) translocations 51
- 4.2 Robertsonian translocations 58
5 Inversions and recombinant chromosomes  
  5.1 Risks of spontaneous abortions and liveborn abnormal offspring  
  5.2 Pericentric inversions and their recombinants  
  5.3 Paracentric inversions and their recombinants  

6 Visible deletions, duplications and insertions  
  6.1 Definitions  
  6.2 Visible duplications  
  6.3 Balanced insertions  

7 Unidentifiable marker chromosomes, derivative chromosomes, chromosomes with additional material and rings  
  7.1 Marker chromosomes  
  7.2 Derivative chromosomes  
  7.3 Chromosomes with additional material  
  7.4 Ring chromosomes  
  7.5 Homogenously staining regions  

8 Isochromosomes, dicentric chromosomes and pseudodicentric chromosomes  
  8.1 Isochromosomes/dicentric chromosomes  
  8.2 Pseudodicentric chromosomes  

9 Composite karyotypes and other complex rearrangements  
  9.1 Composite karyotypes  
  9.2 Complex rearrangements  

10 Sex chromosome abnormalities  
  10.1 X chromosome aneuploidies – female phenotypes  
  10.2 X and Y chromosome aneuploidies – male phenotypes  
  10.3 X chromosome structural abnormalities  
  10.4 Y chromosome structural abnormalities  
  10.5 46,XX males and 46,XY females  
  10.6 X chromosome translocations  

11 Fetal demises/spontaneous abortions  
  11.1 Aneuploid rate  
  11.2 Confined placental mosaicism  
  11.3 Hydatidiform moles  
  11.4 Monosomy X in a fetus  
  11.5 Trisomies in a fetus  
  11.6 Double trisomy  
  11.7 Triploidy  
  11.8 Tetraploidy  

12 Uniparental disomy  
  12.1 Uniparental disomy of chromosome 14  
  12.2 Uniparental disomy of chromosome 15  
  12.3 Uniparental disomy of chromosome 11p15
## Section 2: Fluorescence In Situ Hybridization (FISH) Analysis

13 Metaphase analysis

13.1 Introduction 163
13.2 Reporting normal results 164
13.3 Common disclaimers 166
13.4 Microdeletions 167
13.5 Microduplications 190
13.6 Fluorescence in situ hybridization for chromosome identification 198
13.7 Subtelomere fluorescence in situ hybridization analysis 200

14 Interphase analysis

14.1 Introduction 205
14.2 Example report of interphase analysis 206
14.3 Common disclaimers 207
14.4 Reporting normal results 208
14.5 Abnormal prenatal/neonatal results 211
14.6 Abnormal product of conception FISH abnormalities 218
14.7 Molar pregnancies 222
14.8 Preimplantation genetic diagnosis 222

15 Integrated chromosome and FISH analyses

15.1 ISCN rules and reporting normal results by chromosomes and FISH 232
15.2 ISCN rules and reporting abnormal chromosomes and FISH 233
15.3 ISCN rules and reporting of chromosomes and subtelomere FISH 237

## Section 3: Chromosomal Microarray Analysis (CMA)

16 Bacterial artificial chromosome, oligoarray and single nucleotide polymorphism array methodologies for analysis

16.1 Introduction 245
16.2 Clinical utility of chromosomal microarray analysis 250
16.3 Guidelines for classification states 251
16.4 ISCN rules and reporting of normal results 252
16.5 Comments, disclaimers and recommendations 253

17 Microarray abnormal results

17.1 Reporting of abnormal results 257
17.2 Loss or gain of a single chromosome 258
17.3 Loss or gain of a whole chromosome complement 262
17.4 Microdeletions 263
17.5 Microduplications 265
17.6 Derivative chromosomes 267
17.7 Variants of unknown significance 269
17.8 Uniparental disomy/loss of heterozygosity/regions of homozygosity 269
17.9 Mosaicism 271
17.10 Common comments in abnormal reports 273
17.11 Microarrays with concurrent FISH studies and/or chromosome studies 274
17.12 Microarrays with concurrent parental studies 274
17.13 Preimplantation genetic diagnosis testing 275
17.14 Non-invasive prenatal testing 276

18 Pathogenic chromosomal microarray copy number changes by chromosome order 285
18.1 Chromosome 1 285
18.2 Chromosome 2 287
18.3 Chromosome 3 289
18.4 Chromosome 4 290
18.5 Chromosome 5 291
18.6 Chromosome 7 292
18.7 Chromosome 8 293
18.8 Chromosome 14 294
18.9 Chromosome 15 294
18.10 Chromosome 16 296
18.11 Chromosome 17 298
18.12 Chromosome 19 301
18.13 Chromosome 22 302
18.14 Chromosome X 306

19 Integrated reports with cytogenetics, FISH and microarrays 315
19.1 Reporting of a deletion 315
19.2 Reporting of a supernumerary chromosome 316
19.3 Reporting of an unbalanced translocation – deletion/duplication 318
19.4 Reporting of multiple abnormal cell lines 322

Part 2: Acquired Abnormalities in Hematological and Tumor Malignancies 325

Section 1: Chromosome Analysis 327

20 Introduction 329
20.1 Description of World Health Organization classification for hematological malignancies 332
20.2 Description of different tumor types with significant cytogenetic abnormalities 332
20.3 Set-up and analysis of specific cultures for optimal results 333
20.4 Nomenclature rules for normal and simple abnormal results 336
20.5 Common report comments for hematological malignancies 338

21 Results with constitutional or other non-neoplastic abnormalities 347
21.1 Possible constitutional abnormalities observed 347
21.2 Age-related abnormalities 349
21.3 Non-clonal aberrations 351
21.4 No growth and poor growth 354
22 Cytogenetic abnormalities in myeloid disorders 357
22.1 Introduction to myeloid disorders 357
22.2 Individual myeloid abnormalities by chromosome order 360

23 Cytogenetic abnormalities in lymphoid disorders 395
23.1 Introduction to lymphoid disorders 395
23.2 Hyperdiploidy and hypodiploidy 396
23.3 Individual lymphoid abnormalities by chromosome order 398

24 Common biphenotypic abnormalities and secondary changes 423
24.1 Translocation (4;11)(q21;q23) 423
24.2 Del(9q) 424
24.3 Translocation (11;19)(q23;p13.3) 424
24.4 Del(12)(p11.2p13) 425
24.5 Trisomy 15 425
24.6 i(17q) 426

25 Reporting complex abnormalities and multiple cell lines 429
25.1 Stemline and sideline abnormalities 430
25.2 Unrelated abnormal clones 434
25.3 Composite karyotypes 435
25.4 Double minute chromosomes 436
25.5 Modal ploidy numbers 438
25.6 Multiple abnormal cell lines indicative of clonal evolution 440

26 Breakage disorders 445
26.1 Ataxia telangiectasia 445
26.2 Bloom syndrome 446
26.3 Fanconi anemia 447
26.4 Nijmegen syndrome 448

27 Cytogenetic abnormalities in solid tumors 451
27.1 Clear cell sarcoma 451
27.2 Chondrosarcoma 452
27.3 Ewing sarcoma 453
27.4 Liposarcoma 453
27.5 Neuroblastoma 454
27.6 Rhabdomyosarcoma 455
27.7 Synovial sarcoma 456
27.8 Wilms tumor 456

Section 2: Fluorescence In Situ Hybridization (FISH) Analysis 459

28 Introduction to FISH analysis for hematological disorders and solid tumors 461
28.1 General results 462
28.2 Bone marrow transplantation results 468
29 Recurrent FISH abnormalities in myeloid disorders  471
  29.1 Individual abnormalities in myeloid disorders by chromosome order  471
  29.2 Biphenotypic and therapy-related abnormalities  491
  29.3 Panels of probes  492

30 Recurrent FISH abnormalities in lymphoid disorders  499
  30.1 Individual abnormalities in lymphoid disorders by chromosome order  499
  30.2 Panels of probes  520

31 Integrated reports with cytogenetics and FISH in hematological malignancies  531
  31.1 Translocation (9;22) with BCR/ABL1 FISH analysis  531
  31.2 Monosomy 7 with a marker chromosome and chromosome 7 FISH analysis  532
  31.3 Complex abnormalities with the MDS FISH panel  532
  31.4 Complex abnormalities with ALL FISH panel  533
  31.5 Complex abnormalities with MM FISH panel  535
  31.6 Complex abnormalities with AML FISH panel  536
  31.7 Complex abnormalities with AML FISH panel in therapy-related disease  537

32 Recurrent FISH abnormalities in solid tumors using paraffin-embedded tissue  541
  32.1 Ewing sarcoma  544
  32.2 Liposarcoma  545
  32.3 Neuroblastoma  546
  32.4 Non-small cell lung cancer  547
  32.5 Oligodendroglioma  552
  32.6 Rhabdomyosarcoma  554
  32.7 Synovial sarcoma  554

33 Breast cancer – HER2 FISH analysis  559
  33.1 Common report comments  560
  33.2 Example HER2 reports  561
  33.3 Genetic heterogeneity  563

34 Bladder cancer FISH analysis  569
  34.1 Common report comments  570
  34.2 Example reports  570

Section 3: Chromosomal Microarray Analysis (CMA)  577

35 Chromosomal microarray analysis for hematological disorders  579
  35.1 Introduction  579
  35.2 Categories of abnormalities  580
  35.3 Complex abnormalities throughout the genome, chromothripsis and homozygosity  581
  35.4 Normal results and disclaimers  582
  35.5 Example abnormal results in hematological malignancies  583
36 Chromosomal microarrays for tumors  595
   36.1 Introduction and disclaimers  595
   36.2 Breast cancer  596
   36.3 Lung cancer  604
   36.4 Colon cancer  606
   36.5 Prostate cancer  607
   36.6 Unspecified tumor present  607

37 Integrated reports with chromosomes, FISH and microarrays  611
   37.1 Homozygous deletion of 9p21 identified by FISH and CMA  611
   37.2 Identifying marker chromosomes by chromosome analysis, FISH and CMA  612
   37.3 Unbalanced translocation identification by chromosomes, FISH and CMA  614

Appendix 1: Example assay-specific reagent (ASR) FISH validation plan for constitutional disorders and hematological malignancies on fresh tissue  617

Glossary  623
Index  641